Review
Version 1
Preserved in Portico This version is not peer-reviewed
Current and Novel Alkylators in Multiple Myeloma
Version 1
: Received: 3 March 2021 / Approved: 4 March 2021 / Online: 4 March 2021 (10:02:33 CET)
A peer-reviewed article of this Preprint also exists.
Schjesvold, F.; Oriol, A. Current and Novel Alkylators in Multiple Myeloma. Cancers 2021, 13, 2465. Schjesvold, F.; Oriol, A. Current and Novel Alkylators in Multiple Myeloma. Cancers 2021, 13, 2465.
Abstract
A large number of novel treatments for myeloma have been developed and approved, however alkylating drugs continue to be part of standard regimens, additionally, novel alkylators are currently being developed. We performed a non-systematized literary search for relevant papers and communications at large conferences, as well as exploiting the authors knowledge of the field to review the history, current use and novel concepts around traditional alkylators cyclophosphamide, bendamustine and melphalan and current data on the newly developed pro-drug melflufen. Even in the era of targeted treatment and personalized medicine, alkylating drugs continue to be part of standard-of-care in myeloma, and new alkylators are coming to the market.
Keywords
alkylator; myeloma; melflufen; melphalan; bendamustine; cyclophosphamide
Subject
Medicine and Pharmacology, Immunology and Allergy
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
